Dr. Anastasios Manessis, MD

Medicare patients and services

Medicare patients, 2024

1,331

Services billed

26,222

Patients’ average age

73

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 29 companies reported 346 payments worth $174,540 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 16 industry-funded studies in 2025, from 8 companies. The companies reported $1,054,361 in research payments for these studies, mostly to the institutions running them.

• A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and safety of tirzepatide once weekly compared to placebo in adult participants with type 1 diabetes a…
  Eli Lilly and Company
• A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
  AbbVie Inc. · Active, not recruiting · NCT06345339
• A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
  Eli Lilly and Company · Completed · NCT05872620
• Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
  Eli Lilly and Company · Active, not recruiting · NCT06260722
• Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
  Eli Lilly and Company · Active, not recruiting · NCT06297603
• M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
  AbbVie Inc.
• A phase 3, randomized, double-blind, placebo-controlled study to investigate the effect of muvalaplin on the reduction of major adverse cardiovascular events in adults with elevated lipoprotein(a) who have had a prior…
  Eli Lilly and Company
• A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
  Eli Lilly and Company · Completed · NCT05803421
• A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
  Boehringer Ingelheim Pharmaceuticals, Inc.
• Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism
  Ascendis Pharma Endocrinology Inc · Approved for marketing · NCT05654701

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Endocrinology & Diabetes clinicians in New York

• Sherley Abraham, M.D.
• Cesar Abuchaibe, MD
• Deena Adimoolam, MD
• Nidhi Agrawal
• Jeanine B. Albu, M.D.
• Jose O. Aleman-diaz, M.D., PH.D.
• Lynn R. Allen, M.D.
• Laura C. Alonso, M.D.